ES2177755T3 - Nuevos preparados farmaceuticos a base de peptido de activacion de proteina c. - Google Patents

Nuevos preparados farmaceuticos a base de peptido de activacion de proteina c.

Info

Publication number
ES2177755T3
ES2177755T3 ES96901265T ES96901265T ES2177755T3 ES 2177755 T3 ES2177755 T3 ES 2177755T3 ES 96901265 T ES96901265 T ES 96901265T ES 96901265 T ES96901265 T ES 96901265T ES 2177755 T3 ES2177755 T3 ES 2177755T3
Authority
ES
Spain
Prior art keywords
protein
activation peptide
pharmaceutical preparations
new pharmaceutical
preparations based
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96901265T
Other languages
English (en)
Inventor
Johann Eibl
Ludwig Pichler
Hans-Peter Schwarz
Peter Turecek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter AG
Original Assignee
Baxter AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter AG filed Critical Baxter AG
Application granted granted Critical
Publication of ES2177755T3 publication Critical patent/ES2177755T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE PRESENTA EL USO DEL PEPTIDO DE ACTIVACION DE LA PROTEINA C PARA PREPARAR UNA PREPARACION FARMACEUTICA QUE POSEE UNA ACTIVIDAD ANTINOCICEPTIVA. ESTA PREPARACION FARMACEUTICA ES UTIL EN EL TRATAMIENTO DE ESTADOS DOLOROSOS PROVOCADOS POR PROCESOS INFLAMATORIOS AGUDOS O CRONICOS (TALES COMO ARTRITIS REUMATOIDEA, MIOSITIS, GASTRITIS, COLITIS, INFLAMACIONES EN EL TRACTO UROGENITAL).
ES96901265T 1995-01-20 1996-01-12 Nuevos preparados farmaceuticos a base de peptido de activacion de proteina c. Expired - Lifetime ES2177755T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/375,777 US5571786A (en) 1990-08-16 1995-01-20 Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation

Publications (1)

Publication Number Publication Date
ES2177755T3 true ES2177755T3 (es) 2002-12-16

Family

ID=23482293

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96901265T Expired - Lifetime ES2177755T3 (es) 1995-01-20 1996-01-12 Nuevos preparados farmaceuticos a base de peptido de activacion de proteina c.

Country Status (9)

Country Link
US (1) US5571786A (es)
EP (1) EP0804228B1 (es)
JP (1) JP3330953B2 (es)
AT (2) AT409822B (es)
CA (1) CA2209931A1 (es)
DE (1) DE69621591T2 (es)
DK (1) DK0804228T3 (es)
ES (1) ES2177755T3 (es)
WO (1) WO1996022108A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE262041T1 (de) 1997-04-23 2004-04-15 Vlaams Interuniv Inst Biotech Regulationssystem für induzierbare expression von gene mit lambda-ähnlichen promotoren
US6953568B1 (en) * 1998-08-25 2005-10-11 Oklahoma Medical Research Foundation Targeting of molecules to large vessel endothelium using EPCR
JP2002542148A (ja) * 1998-12-21 2002-12-10 イーライ・リリー・アンド・カンパニー 敗血症の処置のための組み合わせ療法
WO2001090342A2 (en) * 2000-05-22 2001-11-29 Johns Hopkins University Genetic engineering of vascular grafts to resist disease
JP4351041B2 (ja) * 2001-06-13 2009-10-28 ザ・ユニバーシティ・オブ・シドニー 傷治癒のための処置および組成物
US20030055003A1 (en) * 2001-07-19 2003-03-20 David Bar-Or Use of copper chelators to inhibit the inactivation of protein C
JP5204947B2 (ja) 2002-11-27 2013-06-05 ディーエムアイ バイオサイエンシズ インコーポレイテッド リン酸受容体化合物の使用、ならびにリン酸受容体化合物を含んでいる、薬学的組成物、スキンケア用の組成物、およびキット
BR112014028852A2 (pt) 2012-05-31 2018-04-24 Asahi Kasei Pharma Corporation agente para o tratamento profilático e/ou terapêutico de dor neuropática periférica causada por agente anticâncer.
AU2013286812B2 (en) 2012-07-04 2017-04-20 Zz Biotech Llc Treatment of inflammatory skin disorders
PT3137102T (pt) 2014-04-16 2021-09-28 Zz Biotech Llc Apc para utilização no tratamento de cicatrização cutânea anormal
PL3131572T3 (pl) 2014-04-16 2022-02-07 Zz Biotech Llc Analog apc do zastosowania w zaleczaniu rany
US11497795B2 (en) 2018-09-28 2022-11-15 Asahi Kasei Pharma Corporation Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU185926B (en) * 1979-09-27 1985-04-28 Agostne Kahan Process for preparing water soluble derivatives of non-steroid antiinflammatory compositions and pharmaceutical compositins containing such derivatives
GB8319538D0 (en) * 1983-07-20 1983-08-24 Beecham Group Plc Compounds
US4658830A (en) * 1984-08-08 1987-04-21 Survival Technology, Inc. Method and apparatus for initiating reperfusion treatment by an unattended individual undergoing heart attack symptoms
US4902614A (en) * 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4849403A (en) * 1985-05-29 1989-07-18 Pentapharm Ag Protein C activator, methods of preparation and use thereof
US4908314A (en) * 1987-07-02 1990-03-13 American National Red Cross Protein C activator
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US5009889A (en) * 1987-12-31 1991-04-23 Oklahoma Medical Research Foundation Treatment of dysfunctional vascular endothelium using activated protein C
JP2739050B2 (ja) * 1988-01-28 1998-04-08 ヘキスト薬品工業株式会社 抗血液凝固剤
DE3804600A1 (de) * 1988-02-13 1989-08-24 Basf Ag Mischung aus einer thrombolytisch wirkenden und einer antithrombotischen substanz
US5093117A (en) * 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
JP2774156B2 (ja) * 1989-09-05 1998-07-09 帝人株式会社 ヒトプロテインｃおよび／または活性化ヒトプロテインｃ様活性を有する蛋白
AT402260B (de) * 1990-08-16 1997-03-25 Immuno Ag Protein c-hältige pharmazeutische präparation

Also Published As

Publication number Publication date
ATA901196A (de) 2002-04-15
JP3330953B2 (ja) 2002-10-07
ATE218368T1 (de) 2002-06-15
EP0804228A1 (en) 1997-11-05
US5571786A (en) 1996-11-05
CA2209931A1 (en) 1996-07-25
DE69621591T2 (de) 2003-01-16
AT409822B (de) 2002-11-25
DK0804228T3 (da) 2002-09-23
EP0804228B1 (en) 2002-06-05
JPH11502508A (ja) 1999-03-02
DE69621591D1 (de) 2002-07-11
WO1996022108A1 (en) 1996-07-25

Similar Documents

Publication Publication Date Title
DE69104777D1 (de) Orale Arzneimittelformen von biologisch aktiven Eiweisstoffen.
UA43348C2 (uk) Водна фармацевтична композиція, що включає фактор росту нерва (варіанти) та ліофілізований фармацевтичний склад
ATE133181T1 (de) Dehydrodidemnin b
ES2177755T3 (es) Nuevos preparados farmaceuticos a base de peptido de activacion de proteina c.
PT1288223E (pt) Derivados de peptidos terapeuticos
FI861210A7 (fi) N,n'-dialkylguanidinodipeptider.
FR2695714B1 (fr) Installation de traitement cryogénique, notamment de distillation d'air.
ES2176456T3 (es) Procedimiento de preparacion de un compuesto inhibidor del vih proteasa.
AU4421585A (en) Potent thymopentin analogs
ZA963826B (en) A method of treatment of mania and bipolar disorder
TR199900661T2 (xx) Cilt enfeksiyonlar�n�n tedavisi amac�yla 1-hidroksi-2-piridonlar�n kullan�m�
DE59410132D1 (de) Humanes zirkulierendes cytokin cc-1
DK403384D0 (da) Enteralt effektivt, biologisk aktivt peptid- eller proteinmiddel ogfremgangsmaader til fremstilling deraf
AU6633596A (en) Improved therapeutic agents
CA2316447A1 (en) Rantes mutants and therapeutic applications thereof
AU6804394A (en) Oral pharmaceutical compositions comprising a protein or peptide, an antibody and polymeric beads
TR199900662T2 (xx) 1-Hidroksi-2-piridonlar�n seborik dermatit tedavisi amac�yla kullan�m�
CA2041380A1 (en) Use of protein c or activated protein c for preparing a pharmaceutical preparation
TR199600583A2 (tr) Farmasötik aktiviteye sahip -amino asitlerin tolere edilebilirliginin arttirilmasi.
KR950700988A (ko) 미생물, 이들의 제조방법 및 이들의 사용(Micro-organisms, preparation method therefor and uses thereof)
DK28886A (da) Derivater af det neutrale macrolid betegnet cp-63693 og farmaceutiske praeparater indeholdende disse
AU6700996A (en) Somatostatin-analogous cyclic peptides with inhibitory activity on growth hormone
AU580890B2 (en) P-acylaminobenzamides
ES2094930T3 (es) Nueva proteina inhibidora de trombina aislada de garrapatas.
EA199600048A2 (ru) N,n-диэтил-8,8-дипропил-2-азаспиро[4,5]декан-2-пропанамин дималеат, фармацевтическая композиция на его основе и способ индуцирования иммуномодуляции